title: Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
authors.forename: Björn
authors.initials: B
authors.lastname: Hackanson
authors.forename: Anja
authors.initials: A
authors.lastname: Rückert
authors.forename: Michael
authors.initials: M
authors.lastname: Lübbert
mesh_terms: D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000209:etiology / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002872:Chromosome Deletion; D002897:Chromosomes, Human, Pair 7; D003561:Cytarabine / Q000008:administration & dosage; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000235:genetics / Q000473:pathology; D007964:Leukocytosis / Q000209:etiology*; D008297:Male; D009006:Monosomy; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012641:Selection, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate